The Quantellect read.As of Nov 19, 2026, 8 active firms cover IDEXX Laboratories Inc: 4 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $670.00 to $800.00, so the covering firms are broadly aligned. The average target of $717.86 sits 4% above the current $691.20. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.98 next quarter toward $16.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Neutral
Strong Buy00%
Buy450%
Neutral450%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$717.86
+3.9% upside
Average target across 7 active firms as of Nov 19, 2026 vs $691.20 current
Highest Target$800.00
Average Target$717.86
Lowest Target$670.00
Detailed analyst forecasts for IDXX
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 4 of 8 active firms rate IDXX a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IDXX EPS & revenue forecast
EPS · NEXT QUARTER
$3.98
Range $3.88 – $4.07 · 8 analysts · +15% YoY
Next period, 8 analysts expect IDEXX Laboratories Inc to earn $3.98 a share (range $3.88 – $4.07), versus $3.47 a year earlier. Full-year consensus is $15.02, growing to $16.89 the year after.
REVENUE · NEXT QUARTER
$1.2B
Range $1.2B – $1.3B · 8 analysts · +9% YoY
Revenue is expected to reach $1.2B (range $1.2B – $1.3B), +8.7% year-over-year. Full-year consensus is $4.8B, rising to $5.2B next year.
Top analysts covering IDEXX Laboratories Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IDXX.
#1
Erin Wright
Morgan Stanley · Rank #81
Buy
$805.00+16.5% to target
Overall win rate
55%
+ Follow
#2
Mark Massaro
BTIG · Rank #220
Buy
$800.00+15.7% to target
Overall win rate
44%
+ Follow
#3
CS
Chris Schott
JP Morgan · Rank #287
Buy
$750.00+8.5% to target
Overall win rate
41%
+ Follow
#4
Jonathan Block
Stifel · Rank #294
Buy
$675.00-2.3% to target
Overall win rate
36%
+ Follow
#5
David Westenberg
Piper Sandler · Rank #314
Neutral
$750.00+8.5% to target
Overall win rate
35%
+ Follow
IDXX stock forecast FAQ
What is IDXX's average 12-month price target?+
The 7 active firms with a live target average $717.86 for IDEXX Laboratories Inc over the next 12 months, ranging from a $800.00 high to a $670.00 low, as of Nov 19, 2026.
Is IDXX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 8 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IDXX?+
The Street-high target is $800.00 (BTIG), and the Street-low is $670.00 (UBS). The average of all 7 active-firm targets is $717.86.
How many active Wall Street firms cover IDXX?+
8 active firms have a recognized rating on IDEXX Laboratories Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IDXX?+
Among analysts who currently cover IDXX, Erin Wright of Morgan Stanley has the strongest overall Quantellect track record (Rank #81). Their current call is Buy with a $805.00 target.
What is IDEXX Laboratories Inc's projected EPS for next quarter?+
The consensus estimate is $3.98 per share (range $3.88 – $4.07) across 8 analysts. Full-year EPS is projected at $15.02, rising to $16.89 the following year.
How much revenue is IDEXX Laboratories Inc expected to report next quarter?+
Consensus revenue is $1.2B (range $1.2B – $1.3B). Full-year revenue is projected at $4.8B, growing to $5.2B next year.
Have analysts been upgrading or downgrading IDXX lately?+
As of Nov 19, 2026, 4 of 8 active firms rate IDXX a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IDXX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.